



25th February 2026

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 544250

The Secretary
National Stock Exchange of India Limited
C-1, Block G, Exchange Plaza,
Bandra-Kurla Complex,
Bandra East, Mumbai - 400 051
Symbol: SANOFICONR

Sub.: Announcement under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release / Media Release

Dear Sir/Madam,

We wish to inform you that the Board of Directors at its meeting held today i.e., Wednesday, 25th February 2026, *inter-alia* considered and approved the Audited Financial Results for the quarter and financial year ended 31st December 2025. In this regard, please find enclosed a press release for your information and record.

Thanking You,

Yours faithfully
For **Sanofi Consumer Healthcare India Limited**

Nikunj Kumar Savaliya
Company Secretary and Compliance Officer
Membership No.: F7048

Press Release**Sanofi Consumer Healthcare India Limited reports****Q4'25 Revenue at ₹2,510 MN up by 47 %, Net Profit at ₹665 MN up by 50% Y-O-Y****FY '25 Revenue at ₹8,784 MN up by 21%, Net Profit at ₹2,401 MN up by 33%****Highlights for the Quarter Y-O-Y:**

- Revenue at ₹2,510 million, a growth of 47%
- Domestic Sales grew by 23%
- Export Sales grew by 9.3x due to low base
- Profit After Tax was up by 50%

Highlights for the Full Year:

- Revenue at ₹8,784 million, a growth of 21%
- Domestic Sales grew by 7%
- Export Sales grew by 158% due to low base
- Profit After Tax was up by 33%
- Dividend per share ₹75

Mumbai, 25 February 2026: Sanofi Consumer Healthcare India Limited (BSE:544250 | NSE: SANOFICONR) releases its financial results for the fourth quarter, demonstrating sustained growth momentum across key business segments. Revenue growth for the quarter stood at 47% year-on-year. Domestic sales grew by 23%, supported by the relaunch of recalled products to the market. Profit after tax (PAT) for Q4 reached ₹665 million, an increase of 50% on a year-on-year basis. For the full year 2025, the Company reported revenue of ₹8,784 million, reflecting a growth of 21% over the previous year. Profit after tax for the year stood at ₹2,401 million, up 33% year-on-year, supported by disciplined cost management and improved product mix. Dividend of ₹75 per share was also declared for the year ended December 31, 2025.

Commenting on the Q4'25 results, **Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited**, said, *"This quarter's performance emphasizes the strength of our core portfolio and the disciplined execution of our growth agenda. Our domestic business has delivered healthy double-digit growth for two successive quarters, complemented by strong contributions from our export markets. The recognition we've earned for elevating our brands and championing the issues*

that matter to consumers is a testament to our teams' commitment. As we continue to invest in our people and our brands, we remain focused on reinforcing our brand fundamentals and driving operational excellence to unlock the next phase of sustainable growth. Guided by science and driven by purpose, we remain committed to simplifying self-care, making it more accessible and effective for every consumer."

Commenting on the full year results, **Amit Jain, Chairman, Sanofi Consumer Healthcare India Limited**, said, *"Our full-year performance reflects the strength of our strategy and the disciplined execution by our teams. By driving sustained growth, deepening penetration of our portfolio and accelerating digital transformation, we delivered meaningful outcomes for all our stakeholders. Our strong financial performance this year enables us to reward shareholders with a healthy dividend of ₹75 per share."*

About Sanofi Consumer Healthcare India Limited.

Sanofi Consumer Healthcare India Limited (SCHIL) emerged as a distinct legal entity following its demerger from Sanofi India Limited on 1st June 2024. SCHIL now operates independently, with a dedicated focus on the Consumer Healthcare sector.

With an agile business model and strong brands, SCHIL is one of the leading players in India's consumer healthcare market. Leveraging its global experience in consumer healthcare, SCHIL aims to enhance customer wellbeing through its portfolio of products which encompasses Allergy, Digestive Wellness, Pain Care and Multivitamins. SCHIL's key brands include Allegra®, DePURA®, Avil® and Combiflam®. They are dedicated to building a healthier future for their customers by empowering people to take control of their health, through self-care and by addressing their everyday health concerns.

Contacts for Media Relations:

Nida Paloba | +91 9821017561 | nida.paloba@sanofi.com

Agency Contacts:

Clayton Dsouza | +91 9930011602 | claytond@avianwe.com

Shrutika Sukhi | +91 9167971057 | shrutikas@avianwe.com